|
 |
Nombre comercial |
|
|
Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.
|
|
Eberelbin |
Irán |
|
Eunexon |
Marruecos |
|
Eurovinorelbin |
Alemania |
|
Navelbin |
Hungría |
|
Navelbine |
Alemania, Arabia Saudita, Argentina, Australia, Austria, Bélgica, Chile, Colombia, Dinamarca, Egipto, Emiratos Árabes Unidos, España, Estados Unidos de América, Finlandia, Francia, Gran Bretaña, Grecia, India, Irán, Irlanda, Islandia, Italia, Luxemburgo, Malasia, Marruecos, México, Noruega, Nueva Zelanda, Polonia, Portugal, Rumania, Suecia, Suiza, Túnez, Turquía |
|
Navildez |
México |
|
Navin |
Alemania |
|
Navirel |
Alemania, Noruega, Suecia |
|
Okabine |
Marruecos |
|
Relbinalur |
Suecia |
|
Renovel |
Turquía |
|
Setroxin |
México |
|
Sulcoline |
Argentina |
|
Tarckorel |
Marruecos, México |
|
Vieby |
México |
|
Viessia |
Colombia, México, Venezuela |
|
Vilne |
Argentina, Ecuador, Marruecos |
|
Vinarine |
Argentina, Marruecos, Venezuela |
|
Vinelbine |
Malasia |
|
Vinilex |
México |
|
Vinkebir |
Argentina, Marruecos |
|
Vinobina |
Colombia |
|
Vinobur |
Suecia |
|
Vinolbin |
Alemania |
|
Vinorel |
Argentina, Marruecos |
|
Vinorelbin |
Alemania, Austria, Bélgica, Ecuador, Islandia, Noruega, Rumania, Suecia, Suiza |
|
Vinorelbina |
Colombia, Ecuador, España, Marruecos, México, Rumania |
|
Vinorelbine |
Argentina, Bélgica, Canadá, Estados Unidos de América, Gran Bretaña, Irán, Nueva Zelanda, Suiza |
|
Vinorgen |
Chile, Marruecos |
|
Zinavin |
Colombia |
|
|
 |
 |
Bibliografía : Vinorelbine tartrate |
|
|
Tipo |
Publicación |
| 84 |
periódico |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 144 |
periódico |
Dine T, Luyckx M, Cazin JC, Goudaliez F, Mallevais ML.
Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags.
Int J Pharm 1991 ; 77: 279-285. |
| 182 |
periódico |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
periódico |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 251 |
periódico |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 307 |
periódico |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 905 |
periódico |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 921 |
periódico |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 1070 |
periódico |
Balthasar JP.
Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium.
Am J Health-Syst Pharm 1999 ; 56: 1891. |
| 1413 |
periódico |
Lieu CL, Chin A, Gill MA.
Five-day stability of vinorelbine in 5% dextrose injection and in 0.9% sodium chloride injection at room temperature.
Int J Pharm Compound 1999 ; 3: 67-68. |
| 1423 |
periódico |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1501 |
periódico |
Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M.
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Int J Pharm 1999 ; 185: 113-121. |
| 1520 |
Laboratorio |
Etude de stabilité des médicaments en Ecoflac®
B Braun 2001 |
| 1625 |
periódico |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1662 |
periódico |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37. |
| 2260 |
Laboratorio |
Stability of vinorelbin "Ebewe" infusion solutions.
Ebewe Pharma 2007 |
| 3128 |
Laboratorio |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013 |
| 3474 |
Laboratorio |
Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009 |
| 3595 |
Laboratorio |
Aciclovir - Summary of Product Characteristics
Hospira 2009 |
| 3641 |
Laboratorio |
Vinorelbine (Navelbine®) - Summary of Product Characteristics
Pierre Fabre 2011 |
| 3644 |
Laboratorio |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3838 |
Laboratorio |
Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007 |
| 4471 |
Laboratorio |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019 |
|
|
